OR-POWIN
7.5.2024 15:01:37 CEST | Business Wire | Press release
Global energy storage platform provider Powin LLC (Powin) today announced its new multi-cell-based hardware platform, the Powin Pod (Pod). Designed for utility-scale projects, Pod takes Powin’s battery energy storage system (BESS) technology to the next level, setting a new standard for energy storage solutions with higher energy density, top-tier safety, reliability and enhanced cost savings. The Pod platform complements Powin's Centipede product line, offering a comprehensive suite of solutions to meet diverse customer requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507995695/en/
Powin's new multi-cell-based hardware platform, the Powin Pod. (Photo: Business Wire)
"We consistently challenge ourselves to improve our products and services to ensure we are continuously delivering nothing short of excellence to both new and existing customers," said Jeff Waters, CEO of Powin. "This next-generation product advancement demonstrates our commitment to bringing the safest and highest quality energy storage solutions to the market, advancing the entire industry as a result."
The new Pod platform is part of a fully integrated Powin energy storage solution that includes an end-to-end offering—spanning StackOS software, system design, delivery, commissioning and long-term service—that will enable Powin to meet growing customer needs with an improved, reliable and energy-dense storage platform. Powin’s proprietary Battery Management System and Energy Management controls comply with robust localized cybersecurity standards and regulations, ensuring superior protection for data privacy and intellectual property, guaranteeing security of customers’ data, operations and investment at all times. Customers who select Pod will benefit from Powin's full authorization to perform long-term services at their site, as well as comprehensive system training from the company. Within a fully integrated solution, Powin delivers safety, availability, insight and flexibility, providing lower risk, enhanced performance and improved revenue generation.
The Powin Pod platform offers benefits such as:
- Higher-density energy storage: Upgraded cell capacity, utilization of cell-to-pack technology and optimized internal space maximizes energy density and results in significant land savings for projects. Powin Pod delivers a 50% increase in energy density from the Powin Centipede platform. This solution and density improvement is available at 2-hour or greater system applications.
- Top-tier safety and reliability: Liquid cooling provides more stable internal battery system temperatures, ensuring enhanced system safety and longevity. Powin complies with the latest and most stringent fire prevention standards such as UL9540A, NFPA 68 and NFPA 69, while having optional class-leading fire suppression at module and container level.
- Enhanced cost savings: Powin Pod’s compact size reduces the amount of land required for installation, and Powin’s faster and lower cost shipping and on-time delivery combined with simplified installation and commissioning processes allow for lower CAPEX and greater customer savings.
With a proven track record of over 17 GWh deployed and under construction worldwide and over six million battery cells monitored, Powin is a trusted and established US-based integrator. Powin provides world-class logistics for on-time delivery, 20-year performance guarantee and long-term service structures and relies on a 24/7 Remote Operations Center and over 500 field service technicians and Authorized Service Providers to ensure optimal system performance.
Powin Pod is now available to order in markets globally and delivery is expected to begin in mid-2025. Starting in 2026, Powin Pod will be manufactured in the US complying with US Domestic Content requirements. To learn more about Powin’s latest product advancements, please visit https://powin.com/powin-pod/ or visit the Powin team at CLEANPOWER 2024 at booth #2645.
About Powin, LLC (Powin)
At Powin, we are advancing the next frontier of energy and changing the way we power our daily lives by ensuring access to clean, resilient, and affordable power. As a global energy storage platform provider, we offer fully integrated battery solutions, software, and services to optimize grid performance and enable the transition to cleaner energy sources. To learn more, please visit www.powin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507995695/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom